VBLT Share Price | Vascular Biogenics Ltd. Stock Analysis & Recommendation

Q: How big is Vascular Biogenics Ltd.?

Market Cap: As of Jun 17, Vascular Biogenics Ltd. has a market capitalization of 0.00, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, the sum of Net Sales is 0.00 Million, and the sum of Net Profit is -12.50 Million.Balance Sheet Snapshot: As of Dec 22, the Shareholder's Funds amount to 22.45 Million, and the Total Assets are 29.66 Million.

Q: Is Vascular Biogenics Ltd. overvalued or undervalued?

As of 28 March 2019, the valuation grade for Vascular Biogenics Ltd. moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company appears to be overvalued given its current financial metrics, including a P/E ratio of -0.0001 and an EV to EBITDA of 0.28, which are both indicative of severe financial distress. Additionally, the negative ROE of -170.61% further underscores the challenges the company faces.In comparison to its peers, Vascular Biogenics Ltd. has a significantly lower P/E ratio than Equillium, Inc. at -5.5396 and OncoCyte Corp. at -2.9218, both of which are also categorized as risky. The company's returns have been dismal, with a year-to-date decline of -99.64% compared to a 12.22% gain in the S&P 500, reinforcing the notion that it is not a viable investment at this time.

Q: Is Vascular Biogenics Ltd. technically bullish or bearish?

As of 16 December 2024, the technical trend for Vascular Biogenics Ltd. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD also shows mild bullishness. However, the daily moving averages are mildly bearish, and the KST is bearish on both weekly and monthly time frames. The Bollinger Bands are sideways weekly but mildly bearish monthly, and there is no trend indicated by Dow Theory or OBV.The company has significantly underperformed compared to the S&P 500, with a year-to-date return of -99.64% versus the S&P 500's 12.22%, and a one-year return of -99.98% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven by mixed signals across various indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

Shareholding (Jun 2024)

FII

5.97%

Held by 44 FIIs

DII

90.7%

Held by 0 DIIs

Promoter

3.33%

How big is Vascular Biogenics Ltd.?

22-Jun-2025

As of Jun 17, Vascular Biogenics Ltd. has a market capitalization of 0.00, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -12.50 million over the latest four quarters. Shareholder's funds are 22.45 million, and total assets are 29.66 million as of Dec 22.

View full answer

Who are in the management team of Vascular Biogenics Ltd.?

22-Jun-2025

As of March 2022, the management team of Vascular Biogenics Ltd. includes Dr. Bennett Shapiro (Non-Executive Independent Chairman), Prof. Dror Harats (CEO), and several Non-Executive Independent Directors: Ms. Ruth Alon, Prof. Ruth Arnon, Dr. Shmuel Ben Zvi, and Dr. Ron Cohen. They oversee the company's strategic direction and operations.

View full answer

Is Vascular Biogenics Ltd. overvalued or undervalued?

20-Sep-2025

As of March 28, 2019, Vascular Biogenics Ltd. is considered a poor investment due to its severe financial distress, indicated by a negative P/E ratio, low EV to EBITDA, and a year-to-date decline of 99.64%, making it overvalued compared to its peers.

View full answer

Is Vascular Biogenics Ltd. technically bullish or bearish?

20-Sep-2025

As of December 16, 2024, Vascular Biogenics Ltd. shows a mildly bearish technical trend with mixed signals across indicators, significantly underperforming the S&P 500 with year-to-date returns of -99.64% compared to its 12.22%.

View full answer

Compare Vascular Biogenics Ltd. with Similar Stocks

Senti Biosciences, Inc.IGC Pharma, Inc.Sensei Biotherapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 0 Million (Micro Cap)

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.49

Return on Equity

-170.61%

Price to Book

0.00

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2024)

Net Profit:

-5 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.0%

6 Months

-99.5%

1 Year

-99.99%

2 Years

-100.0%

3 Years

-100.0%

4 Years

-100.0%

5 Years

-100.0%

Vascular Biogenics Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-3.82%

EBIT to Interest (avg)

-25.30

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.49

Sales to Capital Employed (avg)

0.02

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

5.98%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.00

EV to EBIT

0.28

EV to EBITDA

0.28

EV to Capital Employed

-0.97

EV to Sales

-3.54

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-170.61%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Sideways

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2024

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 44 Foreign Institutions (5.97%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2024 is 0.00% vs -100.00% in Jun 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2024 is -477.78% vs 90.43% in Jun 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.30",
          "val2": "-0.30",
          "chgp": "-1,666.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "-0.30",
          "chgp": "133.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.20",
          "val2": "-0.90",
          "chgp": "-477.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,690,000.00%",
          "val2": "0.00%",
          "chgp": "-2,69,000.00%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is -12.50% vs -11.11% in Dec 2021",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is -8.03% vs -23.55% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.70",
          "val2": "0.80",
          "chgp": "-12.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-31.80",
          "val2": "-28.70",
          "chgp": "-10.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-32.30",
          "val2": "-29.90",
          "chgp": "-8.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-49,928.60%",
          "val2": "-39,057.30%",
          "chgp": "-1,087.13%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'24 - YoY

Jun'24

Jun'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-5.30

-0.30

-1,666.67%

Interest

0.00

Exceptional Items

0.10

-0.30

133.33%

Consolidate Net Profit

-5.20

-0.90

-477.78%

Operating Profit Margin (Excl OI)

-2,690,000.00%

0.00%

-2,69,000.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2024 is 0.00% vs -100.00% in Jun 2023

Consolidated Net Profit

YoY Growth in quarter ended Jun 2024 is -477.78% vs 90.43% in Jun 2023

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'22

Dec'22

Dec'21

Change(%)

Net Sales

0.70

0.80

-12.50%

Operating Profit (PBDIT) excl Other Income

-31.80

-28.70

-10.80%

Interest

0.10

0.00

Exceptional Items

0.00

Consolidate Net Profit

-32.30

-29.90

-8.03%

Operating Profit Margin (Excl OI)

-49,928.60%

-39,057.30%

-1,087.13%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2022 is -12.50% vs -11.11% in Dec 2021

Consolidated Net Profit

YoY Growth in year ended Dec 2022 is -8.03% vs -23.55% in Dec 2021

All Annual Results

Company CV

About Vascular Biogenics Ltd.

Vascular Biogenics Ltd.

Pharmaceuticals & Biotechnology

Vascular Biogenics Ltd. is Israel- based late-stage clinical biopharmaceutical company, focused on the discovery, development and commercialization of treatments for cancer. VBL’s clinical pipeline is based on two distinct platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. The Company has developed two programs based on these platforms an oncology program and an anti-inflammatory program. The Company’s lead oncology product VB-111, is a targeted anti-cancer gene-therapy agent that is positioned to potentially treat a wide range of solid tumors. VBL has also developed platform of investigational orally-available small molecules, designated Lecinoxoids, for the treatment of chronic immune-related indications.

Company Coordinates

Company Details

8 HaSatat St. , MODIIN None : 7178106

Tel: 972 8 9935000

http://www.vblrx.com

Registrar Details

Vascular Biogenics Ltd.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Vascular Biogenics Ltd.?

Watch in Real-Time

Who are in the management team of Vascular Biogenics Ltd.?

Is Vascular Biogenics Ltd. overvalued or undervalued?

Is Vascular Biogenics Ltd. technically bullish or bearish?

Compare Vascular Biogenics Ltd. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Jun 2024

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'24 - YoY

Annual Results Snapshot (Consolidated) - Dec'22

About Vascular Biogenics Ltd.

Company Coordinates